Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 19 de 19 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, López C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiñones C, Ramírez-Viaplana F, Reyes-Urueña J, Riveira-Muñoz E, Ruiz L, Sanz S, Sentís A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, González-Beiras C, Clotet B, for the BCN-PEP CoV2 Research Group. A cluster-randomized trial of hydroxychloroquine for prevention of covid-19. N Engl J Med 2020;384:24 de noviembre. [Ref.ID 103796]
2.Tiene citas relacionadas Cita con resumen
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses M, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, on behalf of the ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014;383:2222-31. [Ref.ID 97734]
3.Tiene citas relacionadas Cita con resumen
Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K, on behalf of the THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-37. [Ref.ID 90874]
4.Tiene citas relacionadas Cita con resumen
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, for the MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41. [Ref.ID 84124]
5.Tiene citas relacionadas
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarín A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen B-Y, for the BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65. [Ref.ID 83712]
6.Tiene citas relacionadas
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarín A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen B-Y, Teppler H, for the BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54. [Ref.ID 83711]
7.Tiene citas relacionadas Cita con resumen
Lazzarín A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B, on behalf of the DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48. [Ref.ID 80494]
8.Tiene citas relacionadas
Clotet B, Bellos N, Molina J-M, Cooper D, Goffard JC, Lazzarín A, Wöhmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E, on behalf of the POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78. [Ref.ID 79754]
10. Cita con resumen
Jaén A, Casabona J, Esteve A, Miró JM, Tural C, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Masabeu A, García I, Dorca E, Altès J, Navarro G, Podzamczer D, Villalonga C, Clotet B, Gatell JM, y el grupo de estudio PISCIS. Características clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCIS. Med Clin (Barc) 2005;124:525-31. [Ref.ID 73498]
11.Tiene citas relacionadas
Clotet B. Comparison of regimens as initial therapy for HIV. N Engl J Med 2004;350:1053. [Ref.ID 70150]
12.Tiene citas relacionadas
Paredes R, Clotet B. Duración de las combinaciones de fármacos antirretrovirales. Med Clin (Barc) 2004;122:696-7. [Ref.ID 70124]
13.Tiene citas relacionadas
Martínez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, Zala C, Domingo P, Vilaró J, Llibre JM, Viciana P, Hertogs K, Boucher C, D'Aquila RT, Clotet B, and the SWATCH Study Team. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med 2003;139:81-9. [Ref.ID 66879]
14.Tiene citas relacionadas Cita con resumen
Lazzarín A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, for the TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95. [Ref.ID 66382]
15. Cita con resumen
Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Batttegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger T V, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirshchel B, for the Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003;163:1220-6. [Ref.ID 66380]
16.Tiene citas relacionadas
Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman D D. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-26. [Ref.ID 50860]
17.Tiene citas relacionadas
Hirsch MS, Conway B, D'Aquila R, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman D D, for the International AIDS Society-USA panel. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA 1998;279:1984-91. [Ref.ID 39053]
18.
Moreno S, Arrizabalaga J, Gatell JM, Clotet B, Aguirrebengoa K, Antela A, Iribarren JA, Laguna F, Miró JM, Ocaña I, Rubio R, Viciana P, Podzamczer D, por el Grupo de Estudio de Sida (GESIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Recomendaciones sobre tratamiento antirretoviral. Med Clin (Barc) 1998;110:109-16. [Ref.ID 36791]
19.
Pigrau C, Llorens A, Arnau JM, Clotet B, Pahissa A. Gangrena periférica secundaria a ergotismo yatrógeno. Med Clin (Barc) 1981;77:85-6. [Ref.ID 6521]
Seleccionar todas
 
 1 a 19 de 19